Saturna Capital Corp Has $30.04 Million Stake in Johnson & Johnson (NYSE:JNJ)

Saturna Capital Corp boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 0.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 185,339 shares of the company’s stock after purchasing an additional 738 shares during the quarter. Saturna Capital Corp’s holdings in Johnson & Johnson were worth $30,036,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. Meridian Financial Partners LLC bought a new stake in Johnson & Johnson during the second quarter worth $1,626,000. Lmcg Investments LLC grew its stake in shares of Johnson & Johnson by 32.7% in the 3rd quarter. Lmcg Investments LLC now owns 87,162 shares of the company’s stock worth $14,125,000 after acquiring an additional 21,471 shares in the last quarter. WealthPlan Investment Management LLC raised its holdings in shares of Johnson & Johnson by 7.3% in the third quarter. WealthPlan Investment Management LLC now owns 61,691 shares of the company’s stock valued at $9,998,000 after purchasing an additional 4,174 shares during the last quarter. Cooper Haims Advisors LLC boosted its holdings in Johnson & Johnson by 6.4% during the first quarter. Cooper Haims Advisors LLC now owns 3,358 shares of the company’s stock worth $531,000 after purchasing an additional 201 shares during the last quarter. Finally, Trajan Wealth LLC grew its position in Johnson & Johnson by 11.3% in the 3rd quarter. Trajan Wealth LLC now owns 32,992 shares of the company’s stock worth $5,347,000 after purchasing an additional 3,341 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $153.28 on Thursday. The stock has a fifty day moving average of $162.10 and a 200-day moving average of $156.01. The stock has a market cap of $369.04 billion, a PE ratio of 22.18, a price-to-earnings-growth ratio of 2.71 and a beta of 0.53. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.21. The firm had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company’s revenue was up 5.2% on a year-over-year basis. During the same period in the prior year, the business posted $2.66 earnings per share. Equities research analysts anticipate that Johnson & Johnson will post 9.93 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.24%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 71.78%.

Wall Street Analysts Forecast Growth

Several research firms have commented on JNJ. TD Securities dropped their target price on shares of Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Sanford C. Bernstein boosted their price objective on Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. Daiwa Capital Markets lowered Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Royal Bank of Canada boosted their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. Finally, The Goldman Sachs Group decreased their price objective on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a report on Friday, July 19th. Seven research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $175.00.

Insider Transactions at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.